Business Wire

• Study shows that FPM data can be reliably and quickly generated even through minimally invasive small-needle biopsies, which may expand the accessibility of FPM to provide personalized treatment validation and recommendations.

• NIMHD-funded study explores the relationship between biomarkers and racial/ethnic differences in response to cancer therapies to address existing health disparities.

• New research builds on a body of clinical evidence published in the... (continue reading...)

OSAKA, Japan--(BUSINESS WIRE)-- The city of Tondabayashi in Osaka is excited to announce a new inbound tour by "SABIWabisabi," aimed at revitalizing the local community. This exclusive tour combines traditional Japanese cultural experiences with gourmet meals using premium ingredients, all set in a historic Japanese house. Reservations open on June 1, 2024.

This press release features multimedia. View the full release here: ... (continue reading...)

CHICAGO--(BUSINESS WIRE)-- Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to oncology guidelines each year make it difficult for the updates to be rapidly... (continue reading...)

TORONTO--(BUSINESS WIRE)-- Postmedia Network Inc., a wholly owned subsidiary of Postmedia Network Canada Corp. (“Postmedia” or “the Company”) today announced that it has closed its previously announced sale of the Winnipeg Sun, The Graphic Leader, Kenora Miner & News and the Winnipeg Press Commercial Print division to the Klein Group Ltd. (the “Klein Group”).

About Postmedia Network Canada Corp.

Postmedia Network Canada Corp. (TSX:PNC.A, PNC.B) is... (continue reading...)

Ankyra Therapeutics will provide an update on the status of the ANK-101 Phase 1 ANCHOR clinical trial at ASCO 2024 and has received approval by FDA and Health Canada to amend the Phase I study to include patients with solid tumors in visceral organs

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced today that it is... (continue reading...)